戴毅大夫的个人网站 pumchdy.haodf.com
医生头像

戴毅   主治医师 讲师

收藏本站

本站已经通过实名认证,所有内容由戴毅大夫本人发表

戴毅 大夫信息中心页

请下载APP

直接与我沟通!

已扫25,472

当前位置: 好大夫在线-智慧互联网医院 > 戴毅大夫个人网站 > 文章列表 > 文章详情

媒体报道

日本加入GSK968 III期临床试验

发表者:戴毅 人已访问

据日本读卖新闻报道:日本将加入GSK968的III期临床试验,拟选择12名患儿参与其中。并且日本厚生省(卫生部)还破天荒的同意:不在国内重新进行I/II期临床试验,承认国外的试验结果,直接进入III期临床试验。

 

报道指出,能够参与这一国际多中心的临床试验的前提是完善的患者登记系统和准确的基因诊断技术。北京协和医院神经科戴毅

 

在这两点上,我国还有所欠缺,需要大家共同努力。

 

原文如下:

Japan to join DMD drug trial / 1st, 2nd phases finished overseas for severe form of muscular dystrophy

Posted by Editorial Staff on Thu (02/17/11) at 01:38 PM on Latest News

The Yomiuri Shimbun
Japan will join an international clinical trial of a drug to treat Duchenne muscular dystrophy being developed by GlaxoSmithKline K.K., a major British pharmaceutical firm, and other entities, according to sources.
The decision is unusual in that Japan will participate in only the third and final phase of the trial, skipping the first and second phases and using data obtained overseas from the initial phases.
Duchenne muscular dystrophy (DMD) is a severe, rapidly worsening form of muscular dystrophy--a hereditary, intractable disease in which patients experience progressive loss of muscle strength.
DMD occurs in young boys and there are estimated to be about 4,000 patients nationwide. From around the age of 10, patients begin to show symptoms such as difficulty walking, which is followed by serious conditions including respiratory and heart failure, gradually developing.
The disease is caused by an absence of dystrophin protein, which supports muscle structure, due to gene mutations. Comprising substances similar to RNA, the candidate drug enables dystrophin to be produced by complementing the mutated genes. Unlike symptomatic treatment, the drug could address the fundamental cause of the disease.
Gene mutations differ slightly between patients and thus the drug must be synthesized accordingly. It is hoped the medication will be effective on a little more than 10 percent of DMD patients, or several hundred people nationwide, the sources said.
Japan's participation was approved after it established satisfactory patient registration and gene analysis systems.
In the first and second phases of the drug trial conducted in Europe, patients reportedly saw their conditions improve with dystrophin produced by their bodies. No major side effects were reported.
About 180 people from 18 nations and territories around the world are expected to take part in the third phase of the clinical trial. In Japan, 12 patients soon will be administered either the new drug or a placebo once a week for about a year to observe changes in muscle strength, the sources said.
According to the Health, Labor and Welfare Ministry, the first and the second phases can be skipped if the safety of a candidate product is confirmed in overseas clinical tests.
This is in line with the guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, agreed on by Japan, the United States and Europe.

问医生

与医生电话交流 开始

网上免费问医生开始

看更多新文章>>

  • 1.扫码下载好大夫App
  • 2.在知识中添加您关注的疾病
  • 3.添加成功后,最新的医生文章,每天推送给您。

发表于:2011-03-05 22:28

发表评论

戴毅大夫的信息

  • 感谢信: 0 感谢信 礼物: 0 礼物
  • 贡献值: 0

戴毅大夫电话咨询

戴毅大夫已经开通电话咨询服务
直接与大夫本人通话,方便!快捷!

网上咨询戴毅大夫

戴毅的咨询范围: 神经系统单基因遗传病,如肌营养不良、先天性肌病、遗传性运动感觉周围神经病(CMT)、遗传性感觉自主神经病、遗传代谢病(脂质沉积病、糖原累积病、线粒体病等) 更多>>

咨询戴毅大夫